DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.

Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...

"The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President, CEO & Director Jay ...

Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

Safety signals with faricimab in routine practice, including intraocular inflammation and endophthalmitis, aligned with prior ...

VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dosefor treatment of wetage-related macular degeneration ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ...

Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Aflibercept 8 mg improved injection intervals in eyes ...